Multi-Modality Quantitative Imaging for Evaluation of Response to Cancer Therapy

用于评估癌症治疗反应的多模态定量成像

基本信息

批准号：
10437852
负责人：
Yong Du
金额：
$ 64.24万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-19 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10437852
关键词：
Adopted Adoption Advanced Malignant Neoplasm Algorithms Alkaline Phosphatase Area Bone neoplasms Clinical Clinical Trials Data Development Evaluation FOLH1 gene Financial compensation Goals Gold Grant Human Image Image Analysis Imaging Device Institution Lesion Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of prostate Measures Metastatic Neoplasm to the Bone Methods Minor Noise PET/CT scan Patients Positron-Emission Tomography Prevalence Prostate Adenocarcinoma Prostate Cancer therapy Prostate-Specific Antigen Protocols documentation Radionuclide Imaging Regimen Serum Markers Software Tools Source System Technetium Tc 99m Medronate Techniques Testing Time Translating Tumor Burden Tumor Volume Vendor Visual advanced disease anatomic imaging anticancer research automated segmentation base bone bone imaging cancer therapy castration resistant prostate cancer clinical practice cost imaging biomarker imaging modality imaging study improved in vivo indexing interest multimodality new therapeutic target novel therapeutics predicting response quantitative imaging quantum reconstruction relative cost response simulation single photon emission computed tomography standard of care targeted treatment treatment response trial comparing uptake

项目摘要

Bone metastases are common in advanced cancers including prostate adenocarcinoma, where there is evidence of bone metastases in more than 70% of patients with advanced disease. Despite their prevalence and the important clinical implications, there is currently no widely accepted quantitative imaging assessment for response to therapy. Assessment of response or progression is typically made based on visual interpretation of bone scintigraphy in conjunction with CT and serum markers. The goal of this project is thus to develop, validate, and advance to clinical practice multi-modality quantitative metrics for assessing response of bone metastases to therapy. Combined SPECT-CT systems and the implementation of robust compensation methods has enabled the development of quantitative SPECT imaging methods, which have recently become clinically available. Here we propose to exploit the nexus of these developments via the following 3 aims. (1) Using simulation and phantom studies, we will first optimize and evaluate methods for quantitative SPECT/CT (QSPECT) imaging of Tc-99m MDP. We propose to expand the phantom studies to a QIN cooperative project in order to evaluate the methods across different scanners and centers. (2) Based on these QSPECT methods, we will develop, optimize, and characterize quantitative bone SPECT indices for assessing response to therapy. Computing these indices will involve semi-automatic segmentation of bone and bone lesions, implemented in an integrated software tool. The indices calculated will include the number of lesions, bone lesion burden, and change in lesion uptake with therapy. We will characterize the variability of the indices using realistic simulations and in pre-therapy test-retest studies. (3) Finally, we will apply the methods and validate them in current clinical trials of new therapeutic regimens for bone metastatic castrate-resistant prostate cancer. In these studies, we will evaluate the methods in terms of time to progression and will compare the methods in vivo to similar quantitative metrics estimated from Na18F PET/CT. We will also investigate the amount of additional information provided by whole-body MRI and PSMA PET/CT. We will make the methods and images available to the QIN and propose to organize challenges of segmentation and response metrics to take advantage of the QIN-wide interest in these areas. Together, these quantitative imaging tools and studies will provide a validated approach for quantitative imaging-based evaluation of response in bone metastases that is readily clinically implementable with only a minor increase in cost relative to clinical standard bone scintigraphy.

项目成果

期刊论文数量（21）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Noise considerations for PET quantification using maximum and peak standardized uptake value.

使用最大和峰值标准化摄取值进行 PET 定量时的噪声考虑因素。

DOI：
10.2967/jnumed.111.101733
发表时间：
2012-07
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
0
作者：
Lodge MA;Chaudhry MA;Wahl RL
通讯作者：
Wahl RL

Factors affecting the stability and repeatability of gamma camera calibration for quantitative imaging applications based on a retrospective review of clinical data.

DOI：
10.1186/s13550-014-0067-x
发表时间：
2014-12
期刊：
EJNMMI research
影响因子：
3.2
作者：
Anizan N;Wang H;Zhou XC;Hobbs RF;Wahl RL;Frey EC
通讯作者：
Frey EC

A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging.

DOI：
10.1088/0031-9155/57/12/3711
发表时间：
2012-06-21
期刊：
Physics in medicine and biology
影响因子：
3.5
作者：
Rong X;Du Y;Frey EC
通讯作者：
Frey EC

Letter: Design flaws in study of differentiating functional abdominal pain, recurrent acute pancreatitis and chronic pancreatitis via radiomics features. Authors' reply.

信件：通过放射组学特征区分功能性腹痛、复发性急性胰腺炎和慢性胰腺炎的研究存在设计缺陷。

DOI：
10.1016/j.ejrad.2020.108871
发表时间：
2020
期刊：
European journal of radiology
影响因子：
3.3
作者：
Faghih,Mahya;Singh,VikeshK;Mashayekhi,Rouzbeh;Parekh,VishwaS;Jacobs,MichaelA;Zaheer,Atif
通讯作者：
Zaheer,Atif

Quo Vadis: PET and Single-Photon Molecular Breast Imaging.

Quo Vadis：PET 和单光子分子乳腺成像。

DOI：
10.2967/jnumed.115.159202
发表时间：
2016
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
0
作者：
Wahl,RichardL
通讯作者：
Wahl,RichardL